Introduction
Systemic autoimmune diseases (SAD) have gained notoriety as being a risk factor for epilepsy. Conversely, recent studies have reported that epilepsy increases the risk of systemic autoimmune diseases [1, 2] . Based on the emerging data, one may speculate that there is an underlying biological mechanism, such as proinflammatory conditions and antibodies, which links epilepsy and SAD [2, 3] . Numerous studies have focused on clarifying this association, as it could help elucidate the different roles of autoAbs and inflammation in epileptogenesis. Additionally, whether age is a risk factor for epilepsy in patients with SAD has also investigated, however, the results were inconsistent [4, 5] .
Considering that a meta-analysis of these results has yet to be done, the aim of this study was to synthesize all of the available data regarding the association between SAD and epilepsy in order to establish an association between the two. We also evaluated the role that young age plays in this association. This study highlights the need for neurologists to pay attention to the underlying SAD in cases of epilepsy.
Methods

Search strategy and selection criteria
The recommendations put forth by both PRISMA (preferred reporting items for systematic reviews and meta-analyses) [6] and MOOSE (meta-analysis of observational studies in epidemiology) [7] were followed. The protocol used in this study was based on the Cochrane Review Methods (www.cochrane-handbook.org). Two electronic databases (Medline and Embase) were searched using a combination of medical subject headings and text words, including autoimmune disease, type 1 diabetes mellitus, rheumatoid arthritis, Crohns disease, ulcerative colitis, inflammatory bowel disease, systemic lupus erythematosus (SLE), antiphospholipid Purpose: To investigate the association between systemic autoimmune diseases (SAD) and epilepsy and to determine whether the strength of this association is increased in the young. Methods: A meta-analysis was done, analyzing the association between epilepsy and SAD using the available data in Medline and Embase through February 2016. We followed the recommendations of the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement and the MOOSE (meta-analysis of observational studies in epidemiology) guidelines. Results: A total of twenty-five studies met the inclusion criteria for this meta-analysis, which included 10,972 patients with epilepsy (PWE) and 2,618,637 patients with SAD. The PWE cohort was shown to have more than a 2.5-fold increased risk of SAD. The patients with SAD were also shown to have a more than 2.5-fold increased risk of epilepsy. The results indicated that patients <20 years of age had a 3-fold increased risk of SAD and epilepsy (OR = 3.04 [95% CI 1.27-7.27], P = 0.01; OR = 3.15 [95% CI 1.92-5.15], P < 0.01; respectively), and these risks were shown to be higher than patients >20 years of age. The PWE cohort had a 2.6-fold increased risk of celiac disease (OR = 2.65 [95% CI 1.41-4.97], P < 0.01). The patients with systemic lupus erythematosus had a 4.5-fold increased risk of epilepsy (OR = 4.57 [95% CI 2.40-8.67], P < 0.01). Conclusions: There is an association between epilepsy and SAD, which was shown to be stronger at a young age.
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syndrome, celiac disease, bullous pemphigoid (BP), Sjö gren syndrome, myasthenia gravis, seizure, and epilepsy from 1980 to 2016 Feb 29 with an English language restriction. The references of each identified publication were also examined for any additional studies. The literature search was performed by two authors independently, in which the abstracts and full texts were screened and the relevant data was extracted. Studies were eligible for inclusion if they reported (1) the number of patients with epilepsy or SAD (2) the control groups or matched groups. Studies would be excluded if (1) they had no controls or only self-control (2) data were not available or full-text cannot be found (3) data were repeated (4) only acute symptomatic seizures, or only specific seizure patterns, or specific epileptic syndromes were included (5) they are reviews, editorials, single cases and case series, studies published only as abstracts, letters, and commentaries. Any disagreements regarding article were resolved through discussion by all authors.
Data extraction
The following information was recorded for both the study groups and the control groups for each of the included studies: first author, year of publication, country, study design, diagnostic criteria of patients, sample size, percentage of females, age, epilepsy occurrences and SAD. The risk of bias was determined using the Newcastle-Ottawa Scale (NOS) in domains of selection, comparability, and outcome [8] . The NOS score was categorized as 1-3, 4-6, or 7-9, and labeled as low, medium, or high quality of evidence.
Statistical analysis
The discontinuous variables were compared using the MantelHaenszel test, the odds ratio (OR) and the 95% confidence interval (CI). The data were analyzed using a random-effect model, taking into consideration the heterogeneity of the study, for example, different areas of study, different races included in the study, and variations in the design and controls used. The occurrences of epilepsy or presence of SAD in patients were used as outcome measures. Subgroup-analysis was also done for patients with a mean age of <20 years and of >20 years as well as patients with different SAD. Considering the lack of studies with paired patients with a mean age of <20 years against patients >20 years, we were unable to use weighted methods in order to find ORs. Instead, an indirect comparison was made in order to compare the odds risk of epilepsy or SAD in different age groups using a common reference (controls)-based indirect comparison meta-analysis. For example, if we tried to indirectly pair A against B, direct evidence was provided by studies that compare A vs C and B vs C, respectively. However, indirect evidence was provided from studies compared A vs C and B vs C and were analyzed jointly. The ITC software (www. cadth.ca) and the Bucher approach were applied for indirect comparisons [9] . The sensitivity analysis was performed in order to test the reliability of the results of the significant findings using a cycle in which a single study was removed and the analysis of 5 or more studies was repeated. If the result of the study did not change significantly upon the removal of a study, the result of the study was thought to have high stability. Publication bias was qualitatively assessed by a visual inspection of the funnel plots.
Results
Identification and description of studies
A total of 6482 unique articles were identified, of which, 83 were potentially relevant to this study. Twenty-five studies met our inclusion criteria for this meta-analysis ( Fig. 1) . The features of the included studies are presented in Table 1 . A total of 10,972 patients with epilepsy and 2,618,637 patients with SAD were included. The majority of the studies came from Europe. The diagnosis of epilepsy in most of the studies, 18 of 25, was based on the International League Against Epilepsy (ILAE) [35] [36] [37] or the International Classification of Diseases, 9th Revision (ICD-9). The diagnosis of SAD in most studies, 19 of 25, was based on a biopsy, positive antibodies and/or ICD-9. Eight of the twenty-five included studies reported the prevalence of celiac disease in patients with epilepsy [10] [11] [12] [13] [14] [15] [16] [17] . Three of the twenty-five studies reported the prevalence of systemic lupus erythematosus [18] , type 1 diabetes mellitus [19] , and rheumatoid arthritis [18, 20] in patients with epilepsy. One study reported the prevalence of epilepsy in multiple SAD [22] . With the exception of one study [22] , two of the twenty-five studies reported the prevalence of epilepsy in patients with systemic lupus erythematosus [21, 23] . Three of the twenty-five studies reported the prevalence of epilepsy in patients with celiac disease [24] [25] [26] . Four of the twenty-five studies reported the prevalence of epilepsy in patients with BP [27] [28] [29] [30] . Four of the twenty-five studies reported the prevalence of epilepsy in patients with inflammatory bowel disease [31, 32] , type 1 diabetes mellitus [33] , and rheumatoid arthritis [34] . Each of the included studies had a NOS score of 4 or more.
The risk of epilepsy and SAD
Overall, PWE were shown to have a 2.6-fold increased risk of SAD (OR = 2.58 [95% CI 1.48-4.50], P < 0.01) (Fig. 2) . Patients with 
Association between the risk of epilepsy and SAD and age
PWE < 20 years of age were shown to have a 3-fold increased risk of SAD (OR = 3.04 [95% CI 1.27-7.27], P = 0.01) (Fig. 3) . PWE > 20 years of age were not shown to have an increased risk of SAD (OR = 1.42 [95% CI 0.60-3.34], P = 0.42) (Fig. 3) . The indirect comparison of PWE < 20 years of age vs with PWE > 20 years of age was then performed (OR = 2.14 [95% CI 0.63-7.28], P = 0.09).
SAD patients < 20 years of age were shown to have a 3-fold increased risk of epilepsy (OR = 3.15 [95% CI 1.92-5.15], P < 0.01) (Fig. 4) . SAD patients > 20 years of age were shown to have a 2-fold increased risk of epilepsy (OR = 2.27 [95% CI 1.43-3.61], P < 0.01) (Fig. 4) . The indirect comparison of SAD patients <20 years of age vs SAD patients >20 years of age was then performed (OR = 1.39 [95% CI 0.71-2.73], P < 0.01).
Sensitivity analysis
No significant change in the result of this study occurred upon the removal of any one study, indicating that these results are stable.
Publication bias
Visual analysis of the funnel plots for each study included in this meta-analysis show that the majority of the studies fall within the 95% CI, with an approximate symmetrical distribution around the Fig. 2 . The risk of between SAD and epilepsy. Adelow et al. [18] was recorded twice because this article has reported two different cases of SAD, of which the data cannot be reasonably integrated. SAD = systemic autoimmune diseases. [ ( F i g . _ 3 ) T D $ F I G ] Fig. 3 . The risk of SAD in epilepsy at different ages. SAD = systemic autoimmune diseases.
[ ( F i g . _ 2 ) T D $ F I G ]
vertical, which indicates that there is no obvious publication bias (Fig. 5 ).
Discussion
Our results indicated that PWE had more than a 2.5-fold increased risk of SAD and that patients with SAD had more than a 2.5-fold increased risk of epilepsy. These results indicate that epilepsy and SAD are associated with each other. We also determined whether age is associated with an increased association between epilepsy and SAD. Our results suggest that patients <20 years of age have an increased risk of epilepsy as compared to patients with SAD > 20 years of age. An indirect comparison was then performed and the results showed that the ORs in patients <20 years of age vs >20 years of age was greater than 1, although the null value of 1 was included (with the smallest p value equal to 0.09). Therefore, the results of this study support that young age is associated with an increased association between epilepsy and SAD.
Several potentially confounding factors might attenuate our findings and are require further discussion. First, the overall increased risk of epilepsy in patients with SAD may also be underestimated. Patients with BP or SLE have been shown to have a higher risk of epilepsy as compared to the overall risk of epilepsy for SAD; however, patients with BP or SLE only contribute to 0.7% of the SAD patient (18,218 of 2,618,637) population. Additionally, patients with BP were divided into the older age group because the ages were >20 years. Therefore, the epileptic risk of SAD patients with a mean age >20 years might be overestimated. In fact, if the BP studies were removed, the OR in the SAD patient population >20 years of age would significantly diminish (OR = 1.83 [95%CI 0.90-3.74], P = 0.10). Second, the diagnostic error and the difference of the diagnostic criteria in the assessment of SAD and epilepsy in the underlying studies are conceivable but they would likely have produced a few effects on the risk estimates because most of the studies provided a common standard of diagnosis. Third, in the control group of the SAD patients >20 years of age, the incidence of epilepsy is 1.01% (2103 of 207,601). However, in the control group of the SAD patients <20 years of age, the incidence of epilepsy is 0.44% (2103 of 207,601). Therefore, the differences between the younger and older SAD patients in regards to epilepsy risk also appeared to be present in the controls. Fourth, this meta-analysis had some general limitations, including no ideal data collection, clinical diversity, methodological diversity and a publication bias due to null or difficult-to-interpret unpublished results, which may decrease the accuracy of estimates. Therefore, these results should be interpreted carefully.
There are several biological mechanisms that could potentially link SAD to epilepsy. First, antibodies may underlie the association between epilepsy and SAD. For example, epilepsy among patients with lupus is associated with a high titer of anticardiolipin antibodies [38] . Additionally, antiphospholipid antibodies (lupus anticoagulant and anticardiolipin antibodies) have been shown to be present in a high proportion of patients treated with antiepileptic drugs (AEDs) [39] . Second, the increased synthesis and the release of pro-inflammatory cytokines and chemokines in patients with SAD result in the onset of seizures [22] . On the other hand, epileptic seizures stimulate the synthesis of pro-inflammatory and pro-convulsive cytokines [3] . Pro-inflammatory cytokines may aggravate SAD. Third, autoimmunity and neuroinflammation are likely important in SAD-related epilepsy, which may also be a result of the cerebrovascular complications of SAD, including systemic lupus erythematosus, Sjö gren syndrome, type 1 diabetes, and inflammatory bowel disease [22] .
Our meta-analysis suggests that clinicians who specialize in epilepsy should pay close attention to insidious SAD and try to diagnose them. Additionally, clinicians who specialize in immune diseases should focus on preventing epilepsy regardless of the patients' age. Future studies are needed to further examine the underlying biological mechanisms of this association and to determine the role that young age plays in this increased risk.
